Key facts
- Tenpoint Therapeutics’s last known valuation is $76.6M (Jul 2023).
- It has raised $312.1M; the latest was Later Stage VC ($235.0M) in Jan 2026.
- Notable investors include F-Prime Capital, Qiming Venture Partners USA, Eight Roads, British Business Bank, Hillhouse Investment Group — 15 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 15 names
- ·Watchlist + deal alerts for Tenpoint Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Tenpoint Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tenpoint Therapeutics
Operator of a biotechnology platform intended to restore vision for people with degenerative ocular diseases. The company's platform offers engineered cell-based therapies and in vivo reprogramming and has a focus on developing systems that can be delivered directly to the eye, bypassing the need for systemic administration, enabling healthcare providers to make a significant impact on the lives of patients with eye diseases.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2019
- Employees
- 78
- Website
- tenpointtherapeutics.com/
- Ownership
- Privately Held (backing)
Tenpoint Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tenpoint Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tenpoint Therapeutics in its N-PORT filings yet. We sweep new filings monthly.